Financials

News Ideas Discussions Technicals Forecast Seasonals

FYB fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Formycon AG engages in the manufacture of biosimilar drugs and formulations. Its product candidates include FYB201, FYB202, FYB203, and FYB205, which focuses in the opthalmology and immunology disease areas. The company was founded by Friedrich Wilhelm Steinweg and Nicolas Combé in 2007 and is headquartered in Munich, Germany.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

FYB does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company